A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.

被引：1
|
作者：
Burnell, M. J.
Shepherd, L.
Gelmon, K.
Bramwell, V.
Walley, B.
Vandenberg, E.
Chalchal, H.
Pritchard, K.
Whelan, T.
Albain, K.
Perez, E.
Rugo, H.
O'Brien, P.
Chapman, J.
Levine, M.
机构：
[1] Queens Univ, Kingston, ON, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Univ Calgary, Calgary, AB T2N 1N4, Canada
[4] St Johns Hosp, St John, NB, Canada
[5] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[6] Sunnybrook Canc Ctr, Toronto, ON, Canada
[7] Hamilton Hlth Sci Ctr, Juravinski Canc Ctr, Hamilton, ON, Canada
[8] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[9] Mayo Clin, Jacksonville, FL 32224 USA
[10] Univ Calif San Francisco, San Francisco, CA 94143 USA
[11] McMaster Univ, Hamilton, ON, Canada
[12] Allan Blair Canc Ctr, Regina, SK, Canada
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P1-13-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-13-01
引用
收藏
页数：2
相关论文
共 41 条
  • [1] A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis
    Burnell, M.
    Levine, M.
    Chapman, J. A.
    Bramwell, V
    Gelmon, K.
    Walley, B.
    Whelan, T.
    Albain, K.
    Perez, E.
    Rugo, H.
    Ding, Z.
    O'Brien, P.
    Shepherd, L.
    Pritchard, K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) : 117 - 117
  • [2] A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
    Burnell, M. J.
    Levine, M. N.
    Chapman, J. A.
    Bramwell, V.
    Vandenberg, T.
    Chalchal, H. I.
    Albain, K.
    Perez, E.
    Rugo, H.
    Pritchard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [4] Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide:: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Fornier, MN
    Seidman, AD
    Theodoulou, M
    Moynahan, ME
    Currie, V
    Moasser, M
    Sklarin, N
    Gilewski, T
    D'Andrea, G
    Salvaggio, R
    Panageas, KS
    Norton, L
    Hudis, C
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (12) : 3934 - 3941
  • [5] A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer.
    Mavroudis, D.
    Malamos, N.
    Boukovinas, I.
    Kakolyris, S.
    Kourousis, C.
    Athanasiadis, A.
    Ziras, N.
    Makrantonakis, P.
    Polyzos, A.
    Christophylakis, C.
    Georgoulias, V.
    [J]. CANCER RESEARCH, 2012, 72
  • [6] Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer
    Goss, P. E.
    Ingle, J. N.
    Chapman, J-A W.
    Ellis, M. J.
    Sledge, G. W.
    Budd, G. T.
    Rabaglio, M.
    Gelmon, K.
    Shepherd, L.
    Pritchard, K. I.
    [J]. CANCER RESEARCH, 2010, 70
  • [7] NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E.
    Rastogi, Priya
    Atkins, James Norman
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan
    Brufsky, Adam
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Perez, Edith A.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial
    Yuan, Peng
    Kang, Yikun
    Ma, Fei
    Fan, Ying
    Wang, Jiayu
    Wang, Xue
    Yue, Jian
    Luo, Yang
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    [J]. JAMA NETWORK OPEN, 2023, 6 (02) : E230122
  • [9] A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Farley, Cindy P.
    Barton, John H.
    Peacock, Nancy W.
    Spigel, David R.
    Greco, F. Anthony
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (03) : 242 - 248
  • [10] Comparison of an AC-Taxane Versus AC-Free Regimen and Paclitaxel Versus Docetaxel in Patients With Lymph Node-Positive Breast Cancer: Final Results of the National Surgical Adjuvant Study of Breast Cancer O 2 Trial, a Randomized Comparative Phase 3 Study
    Watanabe, Toru
    Kuranami, Masaru
    Inoue, Kenichi
    Masuda, Norikazu
    Aogi, Kenjiro
    Ohno, Shinji
    Iwata, Hiroji
    Mukai, Hirofumi
    Uemura, Yukari
    Ohashi, Yasuo
    [J]. CANCER, 2017, 123 (05) : 759 - 768
12345